GSK’s regulatory submission accepted for review by Japanese regulator for use of Nucala…
GSK plc announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted for review a supplementary new drug application (sJNDA) for Nucala (mepolizumab), a…
Read More...
Read More...
